Table 1.
Participant Characteristics
| A-T- N = 1,029 |
A+T- N = 397 |
A+T+ N = 166 |
Whole cohort N = 1,592 |
|||||
| Age; mean (SD) | 64.3 ± 7.2 | 66.6 ± 7.4 | 70.1 ± 6.4 | 65.5 ± 7.4 | ||||
| Sex = male; N (%) | 430 (41.8) | 186 (46.9) | 82 (49.4%) | 698 (43.2%) | ||||
| Years of education; mean (SD) | 14.5 ± 3.6 | 14.6 ± 3.8 | 13.5 ± 4.0 | 14.5 ± 3.7 | ||||
| MMSE; mean (SD) | 28.8 ± 1.4 | 28.3 ± 1.89 | 26.5 ± 2.9 | 28.4 ± 1.9 | ||||
| CDR = 0.5; N (%) | 187 (18.2) | 127 (32.0) | 109 (65.7%) | 423 (26.6%) | ||||
| APOE status; N (%) | N = 1,008 | N = 390 | N = 163 | |||||
| E2|E2 | 6 (0.6) | 0 (0.0) | 0 (0.0%) | 6 (0.4%) | ||||
| E2|E3 | 120 (11.7) | 23 (5.8) | 5 (3.0%) | 148 (9.3%) | ||||
| E2|E4 | 25 (2.4) | 12 (3.0) | 3 (1.8%) | 40 (2.5%) | ||||
| E3|E3 | 591 (57.4) | 154 (38.8) | 41 (24.7%) | 786 (49.4%) | ||||
| E3|E4 | 253 (24.6) | 166 (41.8) | 86(51.8%) | 505 (31.7%) | ||||
| E4|E4 | 13 (1.3) | 35 (8.8) | 28 (16.9%) | 76 (4.8%) | ||||
| FRS; mean (SD) | N = 1,029 | 14.2 ± 4.1 | N = 397 | 15.4 ± 3.8 | N = 166 | 16.5 ± 4.2 | N = 1,319 | 14.8 ± 4.1 |
| PVS-BG; N (%) | N = 1,014 | N = 391 | N = 162 | N = 1,567 | ||||
| 0 | 46 (4.5) | 8 (2.0) | 4 (2.5%) | 58,217.7 (3.7%) | ||||
| 1 | 843 (83.1) | 316 (80.8) | 120 (74.1%) | 1,279 (81.6%) | ||||
| 2 | 108 (10.7) | 48 (12.3) | 24 (14.8%) | 180 (11.5%) | ||||
| 3 | 16 (1.6) | 17 (4.3) | 11 (6.8%) | 44 (2.8%) | ||||
| 4 | 1 (0.1) | 2 (0.5) | 3 (1.9%) | 6 (0.4%) | ||||
| PVS-CS; N (%) | N = 1,014 | N = 391 | N = 162 | N = 1,567 | ||||
| 0 | 111 (10.9) | 35 (9.0) | 8 (4.9%) | 154 (9.8%) | ||||
| 1 | 591 (58.3) | 195 (49.9) | 68 (42.0%) | 854 (54.5%) | ||||
| 2 | 231 (22.8) | 113(28.9) | 48 (29.6%) | 392 (25.0%) | ||||
| 3 | 72 (7.1) | 42 (10.7) | 33 (20.4%) | 147 (9.4%) | ||||
| 4 | 9 (0.9) | 6 (1.5) | 5 (3.1%) | 20 (1.3%) | ||||
| Fazekas DWMH; N (%) | N = 1,014 | N = 391 | N = 162 | N = 1,567 | ||||
| 0 | 366 (36.1) | 105 (26.9) | 34 (21.0%) | 505 (32.2%) | ||||
| 1 | 515 (50.8) | 205 (52.4) | 71 (43.8%) | 791 (50.5%) | ||||
| 2 | 123 (12.1) | 65 (16.6) | 49 (30.2%) | 237 (15.1%) | ||||
| 3 | 10 (1.0) | 16 (4.1) | 8 (4.9%) | 34 (2.2%) | ||||
| Fazekas PVH; N (%) | N = 1,014 | N = 391 | N = 162 | 58 (35.8%) | N = 1,567 | |||
| 0 | 644 (63.5) | 196 (50.1) | 61 (37.7%) | 898 (57.3%) | ||||
| 1 | 281 (27.7) | 141 (36.1) | 39 (24.1%) | 483 (30.8%) | ||||
| 2 | 81 (8.0) | 50 (12.8) | 4 (2.5%) | 170 (10.8%) | ||||
| 3 | 8 (0.8) | 4 (1.0) | 16 (1.0%) | |||||
| CMB lobar; N (%) | N = 1,029 | N = 397 | N = 166 | N = 1,592 | ||||
| <2 | 1,011 (98.3) | 383 (96.5) | 150 (90.4%) | 1,544 (97%-0%) | ||||
| ≥2 | 18 (1.7) | 14 (3.5) | 16 (9.6%) | 48 (3.0%) | ||||
| CMB deep; N (%) | N = 1,029 | N = 397 | N = 166 | N = 1,592 | ||||
| <1 | 1,026 (99.7) | 394 (99.2) | 162 (97.6%) | 1,582 (99.4%) | ||||
| ≥1 | 3 (0.3) | 3 (0.8) | 4 (2.4%) | 10 (0.6%) | ||||
| Lacunes; N (%) | N = 1,020 | N = 393 | N = 163 | N = 1,576 | ||||
| 0 | 946 (92.7) | 343 (87.3) | 149 (91.4%) | 1,438 (91.2%) | ||||
| 1 | 54 (5.3) | 32 (8.1) | 7 (4.3%) | 93 (5.9%) | ||||
| 2 | 14 (1.4) | 8 (2.0) | 4 (2.5%) | 26 (1.6) | ||||
| >2 | 6 (0.6) | 10 (2.5) | 3 (1.8%) | 19 (1.2) | ||||
| WMH volume; mean (SD) | N = 689 | 4,734.7 ± 6,632.2 | N = 279 | 7,389.53 ± 9,823.2 | N = 114 | 8,713.29 ± 10099.3 | N = 082 | 5,838 ± 8,108 |
Abbreviations: CDR = Clinical Dementia Rating; CMB = cerebral microbleed, cSVD = cerebral small vessel disease, DWMH = deep white matter hyperintensity; FRS = Framingham risk score; MMSE = Mini-Mental State Examination; N= number; PVH = periventricular hyperintensity; PVS-BG = perivascular spaces in basal ganglia; PVS-CS = perivascular spaces in centrum semiovale; WMH = white matter hyperintensity.